

To read this article in full, please review your options for gaining access at the bottom of the page.

Access this article on [ScienceDirect](#)

Effects of sildenafil citrate on human hemodynamics

[Graham Jackson, MD](#), [Nigel Benjamin, MD](#), [Neville Jackson, MD](#), [Michael J. Allen, MD](#)

Altmetric 0

DOI: [http://dx.doi.org/10.1016/S0002-9149\(99\)00043-0](http://dx.doi.org/10.1016/S0002-9149(99)00043-0)



Article Info

Abstract Full Text Images References

Abstract

Nitric oxide (NO) induces the formation of intracellular cyclic guanosine monophosphate (cGMP) by guanylate cyclase. Sildenafil, which selectively inhibits phosphodiesterase type 5 (PDE5) found predominantly in the corpora cavernosa of the penis, effectively blocks the degradation of cGMP and enhances erectile function in men with erectile dysfunction. The NO–cGMP pathway also plays an important role in mediating blood pressure. It is, therefore, possible that the therapeutic doses of sildenafil used to treat erectile dysfunction may have clinically significant effects on human hemodynamics. Three studies were undertaken to assess the effects of intravenously, intra-arterially, and orally administered doses of sildenafil on blood pressure, heart rate, cardiac output, and forearm blood flow and venous compliance in healthy men. A fourth study evaluated the hemodynamic effects of intravenous sildenafil in men with stable ischemic heart disease. In healthy men, significant ($p < 0.01$) decreases in supine systolic and diastolic blood pressures were observed with intravenous sildenafil (20, 40, and 80 mg) at the end of the infusion period when plasma levels of sildenafil were highest (mean decreases from baseline of 7.0/6.9 and 9.2/6.7 mm Hg, for the 40- and 80-mg doses, respectively). These changes were transient and not dose related. Modest reductions in systemic vascular resistance also were observed (maximum decrease 16%), although heart rate was not affected by sildenafil administration when compared with placebo. Single oral doses of sildenafil (100, 150, and 200 mg) produced no significant changes in cardiac index from 1–12 hours postdose between placebo- and sildenafil-treated subjects. The approved dosage strengths of sildenafil citrate are 25 mg, 50 mg, and 100 mg. The 80-mg intravenous dose and the 200-mg oral dose of sildenafil produced comparable plasma levels at twice the maximum therapeutic dose (recommended range, 25–100 mg). After brachial artery infusion of sildenafil (up to 300 $\mu\text{g}/\text{min}$), there was a modest vasodilation of resistance arteries and a reversal of norepinephrine-induced precontraction of forearm veins. These hemodynamic effects were similar to but smaller in magnitude than those of nitrates. In a small pilot study of men with ischemic heart disease, decreases from baseline in pulmonary arterial pressure (-27% at rest and -19% during exercise) and cardiac output (-7% at rest and -11% during exercise) were observed after 40-mg intravenous doses of sildenafil. Sildenafil was well tolerated by subjects and patients in all studies, with headache and other symptoms of vasodilation the most commonly reported adverse effects of treatment. Modest, transient hemodynamic changes were observed in healthy men after single intravenous or oral doses of sildenafil even at supratherapeutic doses. In men with stable ischemic heart disease, sildenafil produced modest effects on hemodynamic parameters at rest and during exercise.

To access this article, please choose from the options below

Log In

Email/Username:
 Password:

Purchase access to this article

- [\\$35.95 USD/PDF Download and 24 Hours Online Access](#)

Article Tools

- [PDF \(205 KB\)](#)
- [Download Images \(.ppt\)](#)
About Images & Usage
- [Email Article](#)
- [Add to My Reading List](#)
- [Export Citation](#)
- [Create Citation Alert](#)
- [Cited by in Scopus \(304\)](#)
- [Request Permissions](#)
- [Order Reprints](#)
(100 minimum order)

Related Articles

- Sildenafil citrate and blood-pressure–lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist**
American Journal of Cardiology, Vol. 83, Issue 5
- Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease**
American Journal of Cardiology, Vol. 93, Issue 2
- Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure**
American Journal of Cardiology, Vol. 95, Issue 1
- Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease**
American Journal of Cardiology, Vol. 83, Issue 5
- Cardiovascular effects of sildenafil citrate and recommendations for its use**
American Journal of Cardiology, Vol. 84, Issue 5

[View All](#)

Remember me

Log In

[Forgot password?](#)

Register

[Create a new account](#)

If you are a current subscriber with Society Membership or an Account Number, [claim your access now](#).

Subscribe to this title

[Purchase a subscription](#) to gain access to this and all other articles in this journal.

Institutional Access

[Visit ScienceDirect](#) to see if you have access via your institution.

© 1999 Excerpta Medica Inc. Published by Elsevier Inc. All rights reserved.

< Previous Article

March 4, 1999 Volume 83, Issue 5, Supplement 1, Pages 13–20

Next Article >

Copyright © 2016 [Elsevier](#) Inc. All rights reserved. | [Privacy Policy](#) | [Terms & Conditions](#) | [Use of Cookies](#) | [About Us](#) | [Help & Contact](#)
The content on this site is intended for health professionals.

Advertisements on this site do not constitute a guarantee or endorsement by the journal, Association, or publisher of the quality or value of such product or of the claims made for it by its manufacturer.